Publication | Closed Access

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Advanced Breast CancerBreast OncologyOncologyPlacebo-controlled Phase 3Clinical TrialsBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyHealth Sciences